Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 117
Filter
Add more filters

Publication year range
1.
Phytother Res ; 38(2): 592-619, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37929761

ABSTRACT

Sterols, including ß-sitosterol, are essential components of cellular membranes in both plant and animal cells. Despite being a major phytosterol in various plant materials, comprehensive scientific knowledge regarding the properties of ß-sitosterol and its potential applications is essential for scholarly pursuits and utilization purposes. ß-sitosterol shares similar chemical characteristics with cholesterol and exhibits several pharmacological activities without major toxicity. This study aims to bridge the gap between phytochemistry and current pharmacological evidence of ß-sitosterol, focusing on its anticancer activity and other biomedical properties. The goal is to provide a comprehensive understanding of ß-sitosterol's potential for future translational approaches. A thorough examination of the literature was conducted to gather relevant information on the biological properties of ß-sitosterol, particularly its anticancer therapeutic potential. Various databases were searched, including PubMed/MedLine, Scopus, Google Scholar, and Web of Science using appropriate keywords. Studies investigating the effects of ß-sitosterol on different types of cancer were analyzed, focusing on mechanisms of action, pharmacological screening, and chemosensitizing properties. Modern pharmacological screening studies have revealed the potential anticancer therapeutic properties of ß-sitosterol against various types of cancer, including leukemia, lung, stomach, breast, colon, ovarian, and prostate cancer. ß-sitosterol has demonstrated chemosensitizing effects on cancer cells, interfering with multiple cell signaling pathways involved in proliferation, cell cycle arrest, apoptosis, survival, metastasis invasion, angiogenesis, and inflammation. Structural derivatives of ß-sitosterol have also shown anti-cancer effects. However, research in the field of drug delivery and the detailed mode of action of ß-sitosterol-mediated anticancer activities remains limited. ß-sitosterol, as a non-toxic compound with significant pharmacological potential, exhibits promising anticancer effects against various cancer types. Despite being relatively less potent than conventional cancer chemotherapeutics, ß-sitosterol holds potential as a safe and effective nutraceutical against cancer. Further comprehensive studies are recommended to explore the biological properties of ß-sitosterol, including its mode of action, and develop novel formulations for its potential use in cancer treatment. This review provides a foundation for future investigations and highlights the need for further research on ß-sitosterol as a potent superfood in combating cancer.


Subject(s)
Leukemia , Phytosterols , Prostatic Neoplasms , Humans , Male , Animals , Plant Extracts/pharmacology , Sitosterols/pharmacology , Sitosterols/therapeutic use , Phytochemicals/pharmacology , Phytochemicals/therapeutic use , Ethnopharmacology
2.
Chem Biol Interact ; 365: 110117, 2022 Sep 25.
Article in English | MEDLINE | ID: mdl-35995256

ABSTRACT

Currently, available therapeutic medications are both costly as well as not entirely promising in terms of potency. So, new candidates from natural resources are of research interest to find new alternative therapeutics. A well-known combination is a ß-sitosterol, a plant-derived nutrient with anticancer properties against breast, prostate, colon, lung, stomach, and leukemia. Studies have shown that ß-sitosterol interferes with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis, anti-inflammatory, anticancer, hepatoprotective, antioxidant, cardioprotective, and antidiabetic effects have been discovered during pharmacological screening without significant toxicity. The pharmacokinetic profile of ß-sitosterol has also been extensively investigated. However, a comprehensive review of the pharmacology, phytochemistry and analytical methods of ß-sitosterol is desired. Because ß-sitosterol is a significant component of most plant materials, humans use it for various reasons, and numerous ß-sitosterol-containing products have been commercialized. To offset the low efficacy of ß-sitosterol, designing ß-sitosterol delivery for "cancer cell-specific" therapy holds great potential. Delivery of ß-sitosterol via liposomes is a demonstration that has shown great promise. But further research has not progressed on the drug delivery of ß-sitosterol or how it can enhance ß-sitosterol mediated anti-inflammatory activity, thus making ß-sitosterol an orphan nutraceutical. Therefore, extensive research on ß-sitosterol as an anticancer nutraceutical is recommended.


Subject(s)
Neoplasms , Sitosterols , Apoptosis , Cell Cycle , Humans , Male , Neoplasms/drug therapy , Plant Extracts/pharmacology , Sitosterols/pharmacology , Sitosterols/therapeutic use
3.
Int J Mol Sci ; 22(22)2021 Nov 12.
Article in English | MEDLINE | ID: mdl-34830148

ABSTRACT

Phytosterols constitute a class of natural products that are an important component of diet and have vast applications in foods, cosmetics, and herbal medicines. With many and diverse isolated structures in nature, they exhibit a broad range of biological and pharmacological activities. Among over 200 types of phytosterols, stigmasterol and ß-sitosterol were ubiquitous in many plant species, exhibiting important aspects of activities related to neurodegenerative diseases. Hence, this mini-review presented an overview of the reported studies on selected phytosterols related to neurodegenerative diseases. It covered the major phytosterols based on biosynthetic considerations, including other phytosterols with significant in vitro and in vivo biological activities.


Subject(s)
Brain/metabolism , Neurodegenerative Diseases/prevention & control , Phytosterols/therapeutic use , Phytotherapy/methods , Plants, Medicinal/chemistry , Brain/pathology , Humans , Molecular Structure , Neurodegenerative Diseases/metabolism , Neuroprotective Agents/chemistry , Neuroprotective Agents/pharmacokinetics , Neuroprotective Agents/therapeutic use , Phytosterols/chemistry , Phytosterols/pharmacokinetics , Sitosterols/chemistry , Sitosterols/pharmacokinetics , Sitosterols/therapeutic use , Stigmasterol/chemistry , Stigmasterol/pharmacokinetics , Stigmasterol/therapeutic use
4.
BMC Urol ; 20(1): 86, 2020 Jul 03.
Article in English | MEDLINE | ID: mdl-32620155

ABSTRACT

BACKGROUND: The present clinical trial was conducted to evaluate the efficacy and tolerability of a standardized saw palmetto oil containing 3% ß-sitosterol in the treatment of benign prostate hyperplasia (BPH) and androgen deficiency. METHODS: Subjects aged 40-65 years with symptomatic BPH were randomized to 12-week double-blind treatment with 500 mg doses of ß-sitosterol enriched saw palmetto oil, conventional saw palmetto oil and placebo orally in the form of capsules (n = 33 in each group). BPH severity was determined using the International Prostate Symptom Score (IPSS), uroflowmetry, serum measurement of prostate specific antigen (PSA), testosterone and 5α-reductase. During the trial, the androgen deficiency was evaluated using Aging Male Symptoms (AMS) scale, the Androgen Deficiency in the Aging Male (ADAM) questionnaire, serum levels of free testosterone. RESULTS: Subjects treated with ß-sitosterol enriched saw palmetto oil showed significant decrease in IPSS, AMS and ADAM scores along with reduced postvoiding residual volume (p < 0.001), PSA (p < 0.01) and 5α-reductase from baseline to end of 12-week treatment as compared to placebo. There was also a significant increment in the maximum and average urine flow rate (p < 0.001), and serum free testosterone level of subjects treated with enriched saw palmetto oil as compared to placebo. CONCLUSION: This study demonstrates the efficacy of ß-sitosterol enriched saw palmetto oil superior to conventional oil thus extending the scope of effective BPH and androgen deficiency treatment with improved quality of life through the intake of functional ingredients. TRIAL REGISTRATION: CTRI/2018/12/016724 dated 19/12/2018 prospectively registered. URL: http://ctri.nic.in/Clinicaltrials/advsearch.php.


Subject(s)
Androgens/deficiency , Phytosterols/therapeutic use , Phytotherapy , Plant Extracts/therapeutic use , Plant Oils/therapeutic use , Prostatic Hyperplasia/drug therapy , Sitosterols/therapeutic use , Urological Agents/therapeutic use , Adult , Aged , Double-Blind Method , Humans , Male , Middle Aged , Serenoa , Treatment Outcome
5.
Metab Brain Dis ; 35(6): 1035-1044, 2020 08.
Article in English | MEDLINE | ID: mdl-32363473

ABSTRACT

Traditional Chinese medicine has growing importance in the treatment of ischemia stroke due to its abundance and low drug resistance. In this study, we aim to investigate the therapeutic potential of daucosterol palmitate against ischemia stroke, as well as its neuro-protective mechanism. The dose-response effects of daucosterol palmitate in the protection from brain damage were evaluated in a cerebral ischemia/reperfusion (I/R) rat model. The correlation of neuro-protective effects of daucosterol palmitate with apoptosis inhibition was examined and the possible signaling targets were identified. Our findings revealed that daucosterol palmitate treatment after 2 h' ischemia significantly lowered brain damage, and neuronal cell apoptosis caused by I/R injury in a dose-response mode (20, 40 and 80 mg/kg). Western blot analysis indicated that daucosterol palmitate could reverse the effects of I/R injury on protein expression of PI3K and mTOR, and phosphorylation of Akt. Contrarily, inactivation of PI3K using wortmannin dramatically antagonized the effect of daucosterol palmitate for I/R injury. With these findings, it supports the application potential of daucosterol palmitate in the treatment of ischemia stroke. Besides, the PI3K/Akt/mTOR pathway might be potential cellular targets for daucosterol palmitate.


Subject(s)
Brain Ischemia/drug therapy , Palmitates/therapeutic use , Phosphoinositide-3 Kinase Inhibitors/therapeutic use , Proto-Oncogene Proteins c-akt/antagonists & inhibitors , Reperfusion Injury/drug therapy , Sitosterols/therapeutic use , TOR Serine-Threonine Kinases/antagonists & inhibitors , Animals , Apoptosis/drug effects , Apoptosis/physiology , Brain Ischemia/metabolism , Brain Ischemia/pathology , Dose-Response Relationship, Drug , Male , Neurons/drug effects , Neurons/metabolism , Neurons/pathology , Palmitates/pharmacology , Phosphatidylinositol 3-Kinases/metabolism , Phosphoinositide-3 Kinase Inhibitors/pharmacology , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Proto-Oncogene Proteins c-akt/metabolism , Rats , Rats, Sprague-Dawley , Reperfusion Injury/metabolism , Reperfusion Injury/pathology , Sitosterols/pharmacology , TOR Serine-Threonine Kinases/metabolism
6.
J Leukoc Biol ; 108(2): 509-517, 2020 08.
Article in English | MEDLINE | ID: mdl-32392637

ABSTRACT

Rheumatoid arthritis (RA) is a chronic disease with complex molecular network of pathophysiology, single drug is usually not full satisfactory because it is almost impossible to target the whole molecular network of the disease. Drug combinations that act synergistically with each another is an effective strategy in RA therapy. In this study, we aimed to establish a new strategy to search effective synergized compounds from Chinese herbal medicine (CHM) used in RA. Based on multi-information integrative approaches, imperatorin (IMP) and ß-sitosterol (STO) were predicted as the most effective pair for RA therapy. Further animal experiments demonstrated that IMP+STO treatment ameliorated arthritis severity of collagen-induced arthritis (CIA) rats in a synergistic manner, whereas IMP or STO administration separately had no such effect. RNA sequencing and IPA analysis revealed that the synergistic mechanism of IMP+STO treatment was related to its regulatory effect on 5 canonical signaling pathways, which were not found when IMP or STO used alone. Moreover, LTA, CD83, and SREBF1 were 3 important targets for synergistic mechanism of IMP+STO treatment. The levels of these 3 genes were significantly up-regulated in IMP+STO group compared to model group, whereas IMP or STO administration separately had no effect on them. In conclusion, this study found that IMP and STO were 2 synergistic compounds from the CHM in RA therapy, whose synergistic mechanism was closely related to regulate the levels of LTA, CD83, and SREBF1.


Subject(s)
Arthritis, Experimental/drug therapy , Furocoumarins/pharmacology , Sitosterols/pharmacology , Animals , Arthritis, Experimental/etiology , Arthritis, Experimental/metabolism , Arthritis, Experimental/pathology , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/etiology , Arthritis, Rheumatoid/metabolism , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/metabolism , Computational Biology/methods , Disease Models, Animal , Drug Synergism , Drugs, Chinese Herbal , Furocoumarins/isolation & purification , Furocoumarins/therapeutic use , Male , Phytotherapy , Rats , Severity of Illness Index , Signal Transduction , Sitosterols/isolation & purification , Sitosterols/therapeutic use
7.
J Lipid Res ; 61(6): 830-839, 2020 06.
Article in English | MEDLINE | ID: mdl-32291331

ABSTRACT

Niemann-Pick type C (NPC)1 disease is a rare genetic condition in which the function of the lysosomal cholesterol transporter NPC1 protein is impaired. Consequently, sphingolipids and cholesterol accumulate in lysosomes of all tissues, triggering a cascade of pathological events that culminate in severe systemic and neurological symptoms. Lysosomal cholesterol accumulation is also a key factor in the development of atherosclerosis and NASH. In these two metabolic diseases, the administration of plant stanol esters has been shown to ameliorate cellular cholesterol accumulation and inflammation. Given the overlap of pathological mechanisms among atherosclerosis, NASH, and NPC1 disease, we sought to investigate whether dietary supplementation with plant stanol esters improves the peripheral features of NPC1 disease. To this end, we used an NPC1 murine model featuring a Npc1-null allele (Npc1nih ), creating a dysfunctional NPC1 protein. Npc1nih mice were fed a 2% or 6% plant stanol ester-enriched diet over the course of 5 weeks. During this period, hepatic and blood lipid and inflammatory profiles were assessed. Npc1nih mice fed the plant stanol-enriched diet exhibited lower hepatic cholesterol accumulation, damage, and inflammation than regular chow-fed Npc1nih mice. Moreover, plant stanol consumption shifted circulating T-cells and monocytes in particular toward an anti-inflammatory profile. Overall, these effects were stronger following dietary supplementation with 6% stanols, suggesting a dose-dependent effect. The findings of our study highlight the potential use of plant stanols as an affordable complementary means to ameliorate disorders in hepatic and blood lipid metabolism and reduce inflammation in NPC1 disease.


Subject(s)
Dietary Supplements , Niemann-Pick Disease, Type C/drug therapy , Sitosterols/pharmacology , Animals , Cholesterol/metabolism , Disease Models, Animal , Liver/drug effects , Liver/metabolism , Male , Mice , Niemann-Pick Disease, Type C/metabolism , Sitosterols/therapeutic use , Sphingolipids/metabolism
8.
Biochem J ; 474(17): 2993-3010, 2017 08 17.
Article in English | MEDLINE | ID: mdl-28739601

ABSTRACT

Arthritis is a chronic inflammatory disease which reduces the life quality of affected individuals. Therapeutic tools used for treating inflammatory pain are associated with several undesirable effects. Buddleja thyrsoides Lam., known as 'Barbasco' or 'Cambara', is mostly used in several disorders and possesses antirheumatic, anti-inflammatory, and analgesic properties. Here, we investigated the antinociceptive and anti-inflammatory effects of the B. thyrsoides crude extract applied orally and topically in acute pain models and an arthritic pain model induced by complete Freund's adjuvant (CFA) paw injection in male mice (25-30 g). The high-performance liquid chromatography (HPLC) of the B. thyrsoides extract crude revealed the presence of the lupeol, stigmasterol, and ß-sitosterol. The stability study of the B. thyrsoides gel did not show relevant changes at low temperatures. The oral treatment with the B. thrysoides extract prevented the capsaicin-induced spontaneous nociception and the acetic acid-induced abdominal writhing, but did not alter the thermal threshold in the tail immersion test. The B. thyrsoides antinociceptive effect was not reversed by naloxone in the capsaicin test. The B. thyrsoides oral or topical treatment reversed the CFA-induced mechanical allodynia and thermal hyperalgesia with maximum inhibition (Imax) of 69 ± 6 and 68 ± 5% as well as 78 ± 15 and 87 ± 12%, respectively. Moreover, the topical but not oral treatment inhibited the CFA-induced cell infiltration, but did not reduce the paw edema significantly. The oral treatment with B. thyrsoides did not cause adverse effects. These findings suggest that the oral or topical treatment with B. thyrsoides presents antinociceptive actions in an arthritic pain model without causing adverse effects.


Subject(s)
Analgesics, Non-Narcotic/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Arthritis, Experimental/drug therapy , Buddleja/chemistry , Plant Extracts/therapeutic use , Plant Leaves/chemistry , Acute Pain/drug therapy , Administration, Cutaneous , Administration, Oral , Analgesics, Non-Narcotic/administration & dosage , Analgesics, Non-Narcotic/adverse effects , Analgesics, Non-Narcotic/chemistry , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Brazil , Buddleja/growth & development , Drug Stability , Drug Storage , Ethnopharmacology , Gels , Hot Temperature/adverse effects , Male , Mice , Pentacyclic Triterpenes/administration & dosage , Pentacyclic Triterpenes/adverse effects , Pentacyclic Triterpenes/analysis , Pentacyclic Triterpenes/therapeutic use , Plant Extracts/administration & dosage , Plant Extracts/adverse effects , Plant Extracts/chemistry , Plant Leaves/growth & development , Sitosterols/administration & dosage , Sitosterols/adverse effects , Sitosterols/analysis , Sitosterols/therapeutic use , Stigmasterol/administration & dosage , Stigmasterol/adverse effects , Stigmasterol/analysis , Stigmasterol/therapeutic use , Viscosity
9.
Medicine (Baltimore) ; 96(29): e7582, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28723796

ABSTRACT

BACKGROUND: Pressure ulcers often seriously affect the quality of life of patients. Moist Exposed Burn Ointment (MEBO) has been developed to treat patients with pressure ulcers. The present study aimed to evaluate the efficacy and safety of MEBO in the treatment of pressure ulcers in Chinese patients. METHODS: Seventy-two patients with pressure ulcers were randomly assigned to 2 groups who received a placebo or MEBO for 2 months. The primary outcomes included the wound surface area (WSA) and pressure ulcer scale for healing (PUSH) tool. The secondary outcomes included a visual analog scale (VAS), questionnaire of ulcer status, and adverse effects. RESULTS: Sixty-seven patients completed the study. After 2 months of treatment, the difference of mean change from the baseline was greater for MEBO (vs placebo) for WSA mean (SD) -6.0 (-8.8, -3.3), PUSH Tool -2.6 (-4.7, -1.5), and VAS score -2.9 (-4.4, -1.7). On the basis of the questionnaire, the pressure ulcers were "completely healed" (50.0% vs 16.7%) (P < .05) in patients after 2 months of treatment with MEBO versus placebo. No major adverse effects were found in the 2 groups. CONCLUSION: We showed that MEBO is effective and well tolerated for improving wound healing in Chinese patients with pressure ulcers.


Subject(s)
Drugs, Chinese Herbal/therapeutic use , Pressure Ulcer/drug therapy , Sitosterols/therapeutic use , Aged , China , Drugs, Chinese Herbal/adverse effects , Female , Humans , Male , Pain Measurement , Pressure Ulcer/pathology , Severity of Illness Index , Sitosterols/adverse effects , Surveys and Questionnaires , Treatment Outcome , Wound Healing/drug effects
10.
Br J Nutr ; 117(6): 839-850, 2017 Mar.
Article in English | MEDLINE | ID: mdl-28382872

ABSTRACT

A study in rodent models showed that phytosterols protected against colon carcinogenesis, probably by inhibiting dysregulated cell cycle progression and inducing cellular apoptosis. However, epidemiological studies on the relationship between phytosterols and colorectal cancer risk are quite limited. The aim of this study was to investigate dietary phytosterol intake in relation to colorectal cancer risk in the Chinese population. A case-control study was conducted from July 2010 to June 2016, recruiting 1802 eligible colorectal cancer cases plus 1813 age (5-year interval) and sex frequency-matched controls. Dietary information was collected by using a validated FFQ. The OR and 95 % CI of colorectal cancer risk were assessed by multivariable logistic regression models. A higher total intake of phytosterols was found to be associated with a 50 % reduction in colorectal cancer risk. After adjusting for various confounders, the OR of the highest quartile intake compared with the lowest quartile intake was 0·50 (95 % CI 0·41, 0·61, P trend<0·01) for total phytosterols. An inverse association was also found between the consumption of ß-sitosterol, campesterol, campestanol and colorectal cancer risk. However, stigmasterol intake was related to an increased risk of colorectal cancer. No statistically significant association was found between ß-sitostanol and colorectal cancer risk. Stratified analysis by sex showed that the positive association of stigmasterol intake with colorectal cancer risk was found only in women. These data indicated that the consumption of total phytosterols, ß-sitosterol, campesterol and campestanol is inversely associated with colorectal cancer risk in a Chinese population.


Subject(s)
Colorectal Neoplasms/prevention & control , Diet , Feeding Behavior , Phytosterols/therapeutic use , Plant Extracts/therapeutic use , Adult , Aged , Aged, 80 and over , Case-Control Studies , China , Energy Intake , Female , Humans , Logistic Models , Male , Middle Aged , Odds Ratio , Phytosterols/pharmacology , Plant Extracts/pharmacology , Risk , Sex Factors , Sitosterols/pharmacology , Sitosterols/therapeutic use
11.
Steroids ; 119: 31-35, 2017 03.
Article in English | MEDLINE | ID: mdl-28119081

ABSTRACT

Alzheimer's disease (AD) is an age-related neurodegenerative disorder characterized by progressive memory decline and cognitive impairment. Amyloid beta (Aß) has been proposed as the causative role for the pathogenesis of AD. Accumulating evidence demonstrates that Aß neurotoxicity is mediated by glutamate excitotoxicity. Daucosterol palmitate (DSP), a plant steroid with anti-glutamate excitotoxicity effect, was isolated from the anti-aging traditional Chinese medicinal herb Alpinia oxyphylla Miq. in our previous study. Based on the anti-glutamate excitotoxicity effect of DSP, in this study we investigated potential benefit and mechanism of DSP in ameliorating learning and memory impairment in AD model rats. Results from this study showed that DSP administration effectively ameliorated Aß-induced learning and memory impairment in rats, markedly inhibited Aß-induced hippocampal ROS production, effectively prevented Aß-induced hippocampal neuronal damage and significantly restored hippocampal synaptophysin expression level. This study suggests that DSP may be a potential candidate for development as a therapeutic agent for AD cognitive decline.


Subject(s)
Cognition Disorders/drug therapy , Learning/drug effects , Memory/drug effects , Sitosterols/therapeutic use , Alzheimer Disease/drug therapy , Alzheimer Disease/metabolism , Alzheimer Disease/physiopathology , Amyloid beta-Peptides/toxicity , Animals , Cognition Disorders/metabolism , Cognition Disorders/physiopathology , Hippocampus/cytology , Male , Neurons/drug effects , Neurons/metabolism , Rats , Rats, Wistar , Reactive Oxygen Species/metabolism , Synaptophysin/metabolism
12.
Nat Prod Commun ; 12(2): 237-240, 2017 Feb.
Article in English | MEDLINE | ID: mdl-30428220

ABSTRACT

Raphanus sativus L. (Brassicaceae) is widely consumed in many different forms worldwide. Its sprouts, in particular, are commonly consumed as a health food. R. stivus sprout has recently been shown to have anti-tumor activity on human colon cancer cells, suggesting that it may have potential use in.cancer prevention and treatment. The extent of this anti-tumor activity and its underlying mechanisms, however, remain to be investigated in other types-of cancer cells. In this study, we showed that the MeOH extract from R. sativus sprout exhibits significant but variable cytotoxic effects on human lung adenocarcinoma cells depending on their p53 status. The MeOH extract decreased the viability of p53-deleted human lung cancer cells (H1299 and Calu-6) by inducing apoptosis; this effect, however, did not occur for wild-type p53 cancer cells (A549), for cells expressing a p53 mutant lacking the C terminus (H1264), or for . non-tumor fibroblast cells (NIH3T3). Phytochemical analyses of the MeOH extract allowed us to identify and isolate 0-sitosterol as a major component of the MeOH extract. Direct treatment with P-sitosterol significantly reduced the viability of Calu-6 cells, suggesting that it may, in part, contribute to R. sativus sprout's anti-tumor activity. This work provides experimental evidence for a novel biological application of R. sativus sprout in treating human lung cancer, and it identifies the main component involved in this effect, further supporting its potential use as a functional food for cancer management.


Subject(s)
Adenocarcinoma of Lung/drug therapy , Plant Extracts/therapeutic use , Raphanus , Tumor Suppressor Protein p53/deficiency , Animals , Apoptosis/drug effects , Cell Line, Tumor , Functional Food , Humans , Mice , NIH 3T3 Cells , Plant Extracts/analysis , Raphanus/chemistry , Sitosterols/therapeutic use
13.
Food Funct ; 7(9): 3999-4011, 2016 Sep 14.
Article in English | MEDLINE | ID: mdl-27711824

ABSTRACT

Banana is an extensively cultivated plant worldwide, mainly for its fruit, while its ancillary product, the banana pseudostem, is consumed as a vegetable and is highly recommended for diabetics in the traditional Indian medicine system. The present study was aimed at elucidating the mechanism of antihyperglycaemia exerted by the ethanol extract of banana pseudostem (EE) and its isolated compounds viz., stigmasterol (C1) and ß-sitosterol (C2), in an alloxan-induced diabetic rat model. Diabetic rats which were administered with C1, C2 and EE (100 and 200 mg per kg b. wt.) for 4 weeks showed reduced levels of fasting blood glucose and reversal of abnormalities in serum/urine protein, urea and creatinine in diabetic rats compared to the diabetic control group of rats. Diabetic symptoms such as polyphagia, polydipsia, polyuria, urine glucose and reduced body weight were ameliorated in the diabetic group of rats fed with EE, C1 and C2 (100 mg per kg b. wt., once daily) for 28 days. The levels of insulin and Hb were also increased, while the HbA1c level was reduced. The altered activities of hepatic marker enzymes viz., aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP); glycolytic enzyme (hexokinase); shunt enzyme (glucose-6-phosphate dehydrogenase); gluconeogenic enzymes (glucose-6-phosphatase, fructose-1,6-bisphosphatase and lactate dehydrogenase) and pyruvate kinase were significantly reverted to normal levels by the administration of EE, C1 and C2. In addition, increased levels of hepatic glycogen and glycogen synthase and the corresponding decrease of glycogen phosphorylase activity in diabetic rats illustrated the antihyperglycaemic potential of EE and its components. The histological observations revealed a marked regeneration of the ß-cells in the drug treated diabetic rats. These findings suggest that EE might exert its antidiabetic potential in the presence of C1 and C2, attributable to the enhanced glycolytic activity, besides increasing the hepatic glucose utilization in diabetic rats by stimulating insulin secretion from the remnant ß-cells.


Subject(s)
Diabetes Mellitus, Experimental/diet therapy , Dietary Supplements , Hypoglycemic Agents/therapeutic use , Musa/chemistry , Plant Extracts/therapeutic use , Sitosterols/therapeutic use , Stigmasterol/therapeutic use , Alloxan , Animals , Biomarkers/blood , Cell Line, Tumor , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Experimental/pathology , Ethnopharmacology , Female , Hyperglycemia/prevention & control , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/adverse effects , Hypoglycemic Agents/isolation & purification , Insulin/metabolism , Insulin Secretion , Insulin-Secreting Cells/metabolism , Insulin-Secreting Cells/pathology , Male , Medicine, Ayurvedic , Musa/growth & development , Plant Extracts/administration & dosage , Plant Extracts/adverse effects , Plant Leaves/chemistry , Plant Leaves/growth & development , Rats , Rats, Wistar , Sitosterols/administration & dosage , Sitosterols/adverse effects , Sitosterols/isolation & purification , Stigmasterol/administration & dosage , Stigmasterol/adverse effects , Stigmasterol/isolation & purification , Toxicity Tests, Acute
14.
J Diet Suppl ; 13(1): 35-92, 2016.
Article in English | MEDLINE | ID: mdl-26268617

ABSTRACT

An evidence-based systematic review of beta-sitosterol, sitosterol (22,23-dihydrostigmasterol, 24-ethylcholesterol) by the Natural Standard Research Collaboration consolidates the safety and efficacy data available in the scientific literature using a validated, reproducible grading rationale. This article includes written and statistical analysis of clinical trials, plus a compilation of expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing.


Subject(s)
Phytotherapy , Plant Extracts/therapeutic use , Sitosterols/therapeutic use , Stigmasterol/therapeutic use , Evidence-Based Medicine , Humans , Plant Extracts/pharmacology , Sitosterols/pharmacology , Stigmasterol/pharmacology
15.
Nutr Cancer ; 67(8): 1214-20, 2015.
Article in English | MEDLINE | ID: mdl-26473555

ABSTRACT

All the currently available cancer therapeutic options are expensive but none of them are safe. However, traditional plant-derived medicines or compounds are relatively safe. One widely known such compound is beta-sitosterol (BS), a plant derived nutrient with anticancer properties against breast cancer, prostate cancer, colon cancer, lung cancer, stomach cancer, ovarian cancer, and leukemia. Studies have shown that BS interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation. Most of the studies are incomplete partly due to the fact that BS is relatively less potent. But the fact that it is generally considered as nontoxic, the opposite of all currently available cancer chemo-therapeutics, is missed by almost all research communities. To offset the lower efficacy of BS, designing BS delivery for "cancer cell specific" therapy hold huge potential. Delivery of BS through liposome is one of such demonstrations that has shown to be highly promising. But further research did not progress neither in the field of drug delivery of BS nor in the field on how BS mediated anticancer activities could be improved, thus making BS an orphan nutraceutical. Therefore, extensive research with BS as potent anticancer nutraceutical is highly recommended.


Subject(s)
Dietary Supplements , Neoplasms/drug therapy , Orphan Drug Production , Sitosterols/therapeutic use , Apoptosis/drug effects , Breast Neoplasms/drug therapy , Breast Neoplasms/prevention & control , Cell Cycle/drug effects , Colonic Neoplasms/drug therapy , Colonic Neoplasms/prevention & control , Drug Delivery Systems , Female , Humans , Leukemia/drug therapy , Leukemia/prevention & control , Liposomes , Lung Neoplasms/drug therapy , Lung Neoplasms/prevention & control , Male , Neoplasms/prevention & control , Phytoestrogens , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/prevention & control , Signal Transduction/drug effects , Sitosterols/administration & dosage
16.
Nutrients ; 7(10): 8518-31, 2015 Oct 15.
Article in English | MEDLINE | ID: mdl-26501315

ABSTRACT

In this study, we evaluated the effects of dietary plant sterols and stanols as their fatty acid esters on the development of experimental colitis. The effects were studied both in high- and low-fat diet conditions in two models, one acute and another chronic model of experimental colitis that resembles gene expression in human inflammatory bowel disease (IBD). In the first experiments in the high fat diet (HFD), we did not observe a beneficial effect of the addition of plant sterols and stanols on the development of acute dextran sulphate sodium (DSS) colitis. In the chronic CD4CD45RB T cell transfer colitis model, we mainly observed an effect of the presence of high fat on the development of colitis. In this HFD condition, the presence of plant sterol or stanol did not result in any additional effect. In the second experiments with low fat, we could clearly observe a beneficial effect of the addition of plant sterols on colitis parameters in the T cell transfer model, but not in the DSS model. This positive effect was related to the gender of the mice and on Treg presence in the colon. This suggests that especially dietary plant sterol esters may improve intestinal inflammation in a T cell dependent manner.


Subject(s)
Colitis/diet therapy , Colon/drug effects , Diet, Fat-Restricted , Diet, High-Fat , Inflammatory Bowel Diseases/pathology , Phytosterols/therapeutic use , T-Lymphocytes/metabolism , Acute Disease , Animals , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Antigens, CD , Brassica rapa/chemistry , Chronic Disease , Colitis/drug therapy , Colitis/etiology , Colitis/immunology , Colon/pathology , Dietary Fats/administration & dosage , Dietary Fats/pharmacology , Dietary Fats/therapeutic use , Esters , Fatty Acids/pharmacology , Fatty Acids/therapeutic use , Fatty Acids, Monounsaturated , Female , Inflammation/diet therapy , Inflammation/drug therapy , Inflammation/immunology , Inflammatory Bowel Diseases/diet therapy , Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/immunology , Male , Mice, Inbred C57BL , Phytosterols/administration & dosage , Phytosterols/pharmacology , Phytotherapy , Plant Oils/chemistry , Rapeseed Oil , Sitosterols/administration & dosage , Sitosterols/pharmacology , Sitosterols/therapeutic use
17.
BMC Complement Altern Med ; 15: 264, 2015 Aug 05.
Article in English | MEDLINE | ID: mdl-26243305

ABSTRACT

BACKGROUND: Arum palaestinum is a plant commonly found in the Middle East that is ingested as an herbal remedy to fight cancer. However, no studies have examined the direct effect of the plant/plant extract on tumor growth in an animal model. METHODS: Verified prostate cancer cells were plated as 3D spheroids to determine the effect of extract from boiled Arum Palaestinum Boiss roots. In addition, male NU/NU mice (8 weeks old) with xenograft tumors derived from the prostate cancer cell line were treated daily with 1000 mg/kg body weight gavage of the suspension GZ17. The tumor growth was measured repeatedly with calipers and the excised tumors were weighed at the termination of the 3 week study. Control mice (10 mice in each group) received vehicle in the same manner and volume. RESULTS: The number of live prostate cancer cells declined in a dose/dependent manner with a 24 h exposure to the extract at doses of 0.015 to 6.25 mg/mL. A fortified version of the extract (referred to as GZ17) that contained higher levels of isovanillin, linolenic acid and ß-sitosterol had a stronger effect on the cell death rate, shifting the percentage of dead cells from 30 % to 55 % at the highest dose while the vehicle control had no effect on cell numbers. When GZ17 was applied to non-cancer tissue, in this case, human islets, there was no cell death at doses that were toxic to treated cancer cells. Preliminary toxicity studies were conducted on rats using an up-down design, with no signs of toxic effect at the highest dose. NU/NU mice with xenograft prostate tumors treated with GZ17 had a dramatic inhibition of tumor progression, while tumors in the control group grew steadily through the 3 weeks. The rate of tumor volume increase was 73 mm(3)/day for the vehicle group and 24 mm(3)/day for the GZ17 treated mice. While there was a trend towards lower excised tumor weight at study termination in the GZ17 treatment group, there was no statistical difference. CONCLUSIONS: Fortified Arum palaestinum Boiss caused a reduction in live cells within prostate cancer spheroids and blocked tumor growth in xenografted prostate tumors in mice without signs of toxicity.


Subject(s)
Antineoplastic Agents , Arum/chemistry , Benzaldehydes , Plant Extracts , Prostatic Neoplasms , Sitosterols , alpha-Linolenic Acid , Animals , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Benzaldehydes/chemistry , Benzaldehydes/pharmacology , Benzaldehydes/therapeutic use , Cell Line, Tumor , Cell Proliferation/drug effects , Male , Mice , Plant Extracts/chemistry , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/pathology , Rats , Sitosterols/chemistry , Sitosterols/pharmacology , Sitosterols/therapeutic use , Spheroids, Cellular , Tumor Cells, Cultured , Xenograft Model Antitumor Assays , alpha-Linolenic Acid/chemistry , alpha-Linolenic Acid/pharmacology , alpha-Linolenic Acid/therapeutic use
18.
Atherosclerosis ; 242(1): 77-86, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26184696

ABSTRACT

OBJECTIVE: Cholesterol analogs have been used to treat hypercholesterolemia. The present study was to examine the effect of dihydrocholesterol (DC) on plasma total cholesterol (TC) compared with that of ß-sitosterol (SI) in hamsters fed a high cholesterol diet. METHODS AND RESULTS: Forty-five male hamsters were randomly divided into 6 groups, fed either a non-cholesterol diet (NCD) or one of five high-cholesterol diets without addition of DC and SI (HCD) or with addition of 0.2% DC (DA), 0.3% DC (DB), 0.2% SI (SA), and 0.3% SI (SB), respectively, for 6 weeks. Results showed that DC added into diet at a dose of 0.2% could reduce plasma TC by 21%, comparable to that of SI (19%). At a higher dose of 0.3%, DC reduced plasma TC by 15%, less effective than SI (32%). Both DC and SI could increase the excretion of fecal sterols, however, DC was more effective in increasing the excretion of neutral sterols but it was less effective in increasing the excretion of acidic sterols compared with SI. Results on the incorporation of sterols in micellar solutions clearly demonstrated both DC and SI could displace the cholesterol from micelles with the former being more effective than the latter. CONCLUSION: DC was equally effective in reducing plasma cholesterol as SI at a low dose. Plasma TC-lowering activity of DC was mediated by inhibiting the cholesterol absorption and increasing the fecal sterol excretion.


Subject(s)
Anticholesteremic Agents/therapeutic use , Cholestanol/therapeutic use , Cholesterol/blood , Hyperlipoproteinemia Type II/diet therapy , Intestinal Absorption/drug effects , Adipose Tissue/drug effects , Adipose Tissue/pathology , Animal Feed/analysis , Animals , Anticholesteremic Agents/administration & dosage , Aortic Diseases/etiology , Aortic Diseases/pathology , Aortic Diseases/prevention & control , Atherosclerosis/etiology , Atherosclerosis/pathology , Atherosclerosis/prevention & control , Bile Acids and Salts/analysis , Cholestanol/administration & dosage , Cholesterol, Dietary/administration & dosage , Cholesterol, Dietary/pharmacokinetics , Cricetinae , Drug Evaluation, Preclinical , Feces/chemistry , Gene Expression Profiling , Hyperlipoproteinemia Type II/blood , Hyperlipoproteinemia Type II/complications , Lipids/blood , Lipoproteins/blood , Liver/chemistry , Liver/pathology , Male , Mesocricetus , Metabolic Networks and Pathways/genetics , Micelles , Molecular Structure , Organ Size/drug effects , Plaque, Atherosclerotic/pathology , RNA, Messenger/biosynthesis , Random Allocation , Sitosterols/administration & dosage , Sitosterols/therapeutic use , Sterols/analysis , Viscera/drug effects , Viscera/pathology
19.
BMC Complement Altern Med ; 15: 50, 2015 Mar 10.
Article in English | MEDLINE | ID: mdl-25886964

ABSTRACT

BACKGROUND: Nardostachys jatamansi DC is a Himalayan medicinal herb that has been described in various traditional systems of medicine for its use in cancer. In view of its traditional claims, and chemical constituents, antioxidant and anticancer activities were evaluated in breast carcinoma. METHODS: Petroleum ether (NJPE), methanol extract (NJM) and subsequent diethyl ether (NJDE), ethyl acetate (NJEA) and aqueous (NJAQ) fractions of roots and rhizomes of N. jatamansi were prepared. Total phenolic, flavonoid content, and antioxidant activities were determined using suitable methods. Antiproliferative activity was assessed in estrogen receptor (ER)-positive (MCF-7) and ER-negative breast carcinoma (MDA-MB-231) cells by MTT and SRB assay. Cell cycle analysis, Hoechst staining, and clonogenic assay were employed to determine the mode of antiproliferative and pro-apoptotic activity in MDA-MB-231 cells. RESULTS: NJM/fractions exhibited prominent antioxidant activity with significant correlation between phenolic content and ABTS (IC50) scavenging (R = -0.9680, P < 0.05), and total antioxidant capacity (R = 0.8396, P > 0.05). In MTT assay, NJM exhibited the highest antiproliferative activity (IC50: 58.01 ± 6.13 and 23.83 ± 0.69 µg/mL in MCF-7 and MDA-MB-231 respectively). Among the fractions, NJPE and NJDE were found to be most potent in MCF-7 (IC50: 60.59 ± 4.78 µg/mL) and MDA-MB-231 (IC50: 25.04 ± 0.90 µg/mL) cells respectively. Statistical analyses revealed NJM and NJDE exhibited significantly higher (P < 0.05) cytotoxicity in MDA-MB-231 cells. Cell cycle analysis demonstrated that NJM, NJPE and NJEA caused G2/M arrest while NJDE caused G0/G1 phase arrest in MDA-MB-231 cells. Further, NJM/fractions induced significant (P < 0.001) cell death by apoptosis characterized by apoptotic morphological changes in Hoechst staining and inhibited long-term proliferation (P < 0.001) of MDA-MB-231 cells in clonogenic assay. Lupeol and ß-sitosterol were identified as anticancer principles in NJM/fractions by HPTLC. CONCLUSION: Our results suggest that NJM/fractions possess significant antiproliferative potential which is mediated through cell cycle perturbation and pro-apoptotic effects in MDA-MB-231 cells. Moreover, this study highlights the antioxidant potential of NJM/fractions which can be attributed to the presence of phenols. NJDE emerged as the most potent fraction and further mechanistic and phytochemical investigations are under way to identify the active principles.


Subject(s)
Antineoplastic Agents, Phytogenic/therapeutic use , Antioxidants/therapeutic use , Breast Neoplasms/drug therapy , Nardostachys/chemistry , Phytotherapy , Plant Extracts/therapeutic use , Polyphenols/therapeutic use , Adenocarcinoma/drug therapy , Adenocarcinoma/metabolism , Antineoplastic Agents, Phytogenic/analysis , Antineoplastic Agents, Phytogenic/pharmacology , Antioxidants/analysis , Antioxidants/pharmacology , Apoptosis/drug effects , Breast Neoplasms/metabolism , Cell Cycle/drug effects , Cell Proliferation/drug effects , Female , Flavonoids/analysis , Flavonoids/pharmacology , Flavonoids/therapeutic use , G1 Phase/drug effects , Humans , MCF-7 Cells , Pentacyclic Triterpenes/analysis , Pentacyclic Triterpenes/pharmacology , Pentacyclic Triterpenes/therapeutic use , Phenols/analysis , Phenols/pharmacology , Phenols/therapeutic use , Plant Extracts/chemistry , Plant Extracts/pharmacology , Plant Roots , Plants, Medicinal , Polyphenols/analysis , Polyphenols/pharmacology , Receptors, Estrogen/metabolism , Rhizome , Sitosterols/analysis , Sitosterols/pharmacology , Sitosterols/therapeutic use
20.
Nutrients ; 7(3): 1672-87, 2015 Mar 06.
Article in English | MEDLINE | ID: mdl-25756784

ABSTRACT

Structures of some bioactive phytochemicals in bran extract of the black rice cv. Riceberry that had demonstrated anti-cancer activity in leukemic cell line were investigated. After saponification with potassium hydroxide, separation of the unsaponified fraction by reversed-phase high performance liquid chromatography (HPLC) resulted in four sub-fractions that had a certain degree of anti-proliferation against a mouse leukemic cell line (WEHI-3 cell), this being IC50 at 24 h ranging between 2.80-467.11 µg/mL. Further purification of the bioactive substances contained in these four sub-fractions was performed by normal-phase HPLC. Structural characterization by gas chromatography-mass spectrometry (GC-MS), liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance spectroscopy (NMR) resulted in, overall, the structures of seven phytosterols and four triterpenoids. Four phytosterols, 24-methylene-ergosta-5-en-3ß-ol, 24-methylene-ergosta-7-en-3ß-ol, fucosterol, and gramisterol, along with three triterpenoids, cycloeucalenol, lupenone, and lupeol, were found in the two sub-fractions that showed strong anti-leukemic cell proliferation (IC50 = 2.80 and 32.89 µg/mL). The other sterols and triterpenoids were campesterol, stigmasterol, ß-sitosterol and 24-methylenecycloartanol. Together with the data from in vitro biological analysis, we suggest that gramisterol is a significant anti-cancer lead compound in Riceberry bran extract.


Subject(s)
Antineoplastic Agents, Phytogenic/therapeutic use , Leukemia/drug therapy , Oryza/chemistry , Phytosterols/therapeutic use , Phytotherapy , Seeds/chemistry , Triterpenes/therapeutic use , Animals , Antineoplastic Agents, Phytogenic/chemistry , Antineoplastic Agents, Phytogenic/isolation & purification , Antineoplastic Agents, Phytogenic/pharmacology , Cell Line, Tumor , Cholesterol/analogs & derivatives , Cholesterol/chemistry , Cholesterol/isolation & purification , Cholesterol/pharmacology , Cholesterol/therapeutic use , Chromatography, High Pressure Liquid , Gas Chromatography-Mass Spectrometry , Mass Spectrometry , Mice , Molecular Structure , Pentacyclic Triterpenes/chemistry , Pentacyclic Triterpenes/isolation & purification , Pentacyclic Triterpenes/pharmacology , Pentacyclic Triterpenes/therapeutic use , Phytosterols/chemistry , Phytosterols/isolation & purification , Phytosterols/pharmacology , Plant Extracts/chemistry , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Sitosterols/chemistry , Sitosterols/isolation & purification , Sitosterols/pharmacology , Sitosterols/therapeutic use , Stigmasterol/analogs & derivatives , Stigmasterol/chemistry , Stigmasterol/isolation & purification , Stigmasterol/pharmacology , Stigmasterol/therapeutic use , Triterpenes/chemistry , Triterpenes/isolation & purification , Triterpenes/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL